These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37863556)

  • 1. Pathologic Evaluation of Therapeutic Biomarkers in Colorectal Adenocarcinoma.
    Baranov E; Nowak JA
    Surg Pathol Clin; 2023 Dec; 16(4):635-650. PubMed ID: 37863556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
    Ye JX; Liu Y; Qin Y; Zhong HH; Yi WN; Shi XY
    World J Gastroenterol; 2015 Feb; 21(5):1595-605. PubMed ID: 25663779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.
    Sehdev A; Cramer HM; Ibrahim AA; Younger AE; O'Neil BH
    Discov Med; 2016 May; 21(117):341-7. PubMed ID: 27355330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Evaluation of Colorectal Adenocarcinoma: Current Practice and Emerging Concepts.
    Nowak JA; Hornick JL
    Surg Pathol Clin; 2016 Sep; 9(3):427-39. PubMed ID: 27523970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of
    Bourhis A; De Luca C; Cariou M; Vigliar E; Barel F; Conticelli F; Marcorelles P; Nousbaum JB; Robaszkiewicz M; Samaison L; Badic B; Doucet L; Troncone G; Uguen A
    J Clin Pathol; 2020 Nov; 73(11):741-747. PubMed ID: 32273401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories.
    Bocciarelli C; Caumont C; Samaison L; Cariou M; Aline-Fardin A; Doucet L; Roudié J; Terris B; Merlio JP; Marcorelles P; Cappellen D; Uguen A
    Hum Pathol; 2021 Aug; 114():99-109. PubMed ID: 34019865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic role of microsatellite instability in colorectal cancer patients.
    Micu BV; Andercou O; Vesa SC; Micu CM; Pop TR; Constantea N
    Ann Ital Chir; 2017; 6():425-432. PubMed ID: 28874631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival.
    Olevian DC; Nikiforova MN; Chiosea S; Sun W; Bahary N; Kuan SF; Pai RK
    Hum Pathol; 2016 Mar; 49():124-34. PubMed ID: 26826419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas.
    Farchoukh L; Kuan SF; Dudley B; Brand R; Nikiforova M; Pai RK
    Am J Surg Pathol; 2016 Oct; 40(10):1390-9. PubMed ID: 27438990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: A single-center retrospective study of 1,834 Chinese patients with Stage I-IV colorectal cancer.
    Guo TA; Wu YC; Tan C; Jin YT; Sheng WQ; Cai SJ; Liu FQ; Xu Y
    Int J Cancer; 2019 Sep; 145(6):1625-1634. PubMed ID: 31162857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer.
    Korphaisarn K; Pongpaibul A; Limwongse C; Roothumnong E; Klaisuban W; Nimmannit A; Jinawath A; Akewanlop C
    World J Gastroenterol; 2015 Jan; 21(3):926-34. PubMed ID: 25624727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
    Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
    Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic and molecular characteristics of synchronous colorectal cancers: heterogeneity of clinical outcome depending on microsatellite instability status of individual tumors.
    Bae JM; Cho NY; Kim TY; Kang GH
    Dis Colon Rectum; 2012 Feb; 55(2):181-90. PubMed ID: 22228162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis.
    Gil-Raga M; Jantus-Lewintre E; Gallach S; Giner-Bosch V; Frangi-Caregnato A; Safont-Aguilera MJ; Garde-Noguera J; Zorraquino-Pina E; García-Martínez M; Camps-Herrero C
    Clin Transl Oncol; 2018 Nov; 20(11):1422-1429. PubMed ID: 29802524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinctive patterns of p53 protein expression and microsatellite instability in human colorectal cancer.
    Nyiraneza C; Jouret-Mourin A; Kartheuser A; Camby P; Plomteux O; Detry R; Dahan K; Sempoux C
    Hum Pathol; 2011 Dec; 42(12):1897-910. PubMed ID: 21665242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
    Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
    Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of metastatic colorectal cancer with synchronous
    Cheng Y; Fang XF; Hu HG; Wang J; Sun LF; Yuan Y
    Immunotherapy; 2020 Mar; 12(4):229-234. PubMed ID: 32172642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update.
    Baraibar I; Ros J; Mulet N; Salvà F; Argilés G; Martini G; Cuadra JL; Sardo E; Ciardiello D; Tabernero J; Élez E
    Expert Rev Mol Diagn; 2020 Jul; 20(7):653-664. PubMed ID: 32552041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency and coexistence of KRAS, NRAS, BRAF and PIK3CA mutations and occurrence of MMR deficiency in Danish colorectal cancer patients.
    Poulsen TS; de Oliveira DVNP; Espersen MLM; Klarskov LL; Skovrider-Ruminski W; Hogdall E
    APMIS; 2021 Feb; 129(2):61-69. PubMed ID: 33075161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.